Cargando…

Reappraisal of role of angiotensin receptor blockers in cardiovascular protection

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have shown cardioprotective and renoprotective properties. These agents are recommended as first-line therapy for the treatment of hypertension and the reduction of cardiovascular risk. Early studies pointed to...

Descripción completa

Detalles Bibliográficos
Autor principal:	Ram, C Venkata S
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104608/ https://www.ncbi.nlm.nih.gov/pubmed/21633521 http://dx.doi.org/10.2147/VHRM.S15787

Ejemplares similares

A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention
por: Wang, Ji-Guang
Publicado: (2009)

Angiotensin II receptor blockers and cardiovascular protection: Focus on left ventricular hypertrophy regression and atrial fibrillation prevention
por: Cuspidi, Cesare, et al.
Publicado: (2008)

The Role of Angiotensin Receptor Blockers in the Personalized Management of Diabetic Neuropathy
por: Kostourou, Danai-Thomais, et al.
Publicado: (2022)

Cardiovascular outcomes with angiotensin II receptor blockers: clinical implications of recent trials
por: Baumhäkel, Magnus, et al.
Publicado: (2011)

Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk
por: Farsang, Csaba
Publicado: (2011)

The Pivotal Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertension Management and Cardiovascular and Renal Protection: A Critical Appraisal and Comparison of International Guidelines
por: Alcocer, Luis Antonio, et al.
Publicado: (2023)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

The use of angiotensin receptor blockers in dementia prevention
por: Müller, Jordana de Araujo, et al.
Publicado: (2023)

Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan
por: Omboni, Stefano, et al.
Publicado: (2018)

To do or not to do: Angiotensin converting enzyme inhibitors/angiotensin receptor blocker in COVID-19 elderly patients
por: Vura, Naga Venkata Rama Krishna, et al.
Publicado: (2021)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Is angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy protective against prostate cancer?
por: Mao, Yeqing, et al.
Publicado: (2016)

Elevated Blood Pressure in the Acute Phase of Stroke and the Role of Angiotensin Receptor Blockers
por: Lattanzi, Simona, et al.
Publicado: (2013)

What is the role of angiotensin receptor blockers in treatment of hyperuricemia coexisting with arterial hypertension?
por: Nieradko-Iwanicka, Barbara
Publicado: (2018)

Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan
por: Omboni, Stefano, et al.
Publicado: (2018)

Potential use of angiotensin receptor blockers in skin pathologies
por: Hedayatyanfard, Keshvad, et al.
Publicado: (2023)

Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq
por: Al-Hussaniy, Hany A., et al.
Publicado: (2023)

Angiotensin receptor blockers and COVID-19
por: Saavedra, Juan M.
Publicado: (2020)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Targeting effective blood pressure control with angiotensin receptor blockers
por: Asmar, R
Publicado: (2006)

Comparative assessment of angiotensin receptor blockers in different clinical settings
por: Verdecchia, Paolo, et al.
Publicado: (2009)

Angiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand?
por: Fuchs, Flávio Danni, et al.
Publicado: (2015)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
por: Moore, Graham J., et al.
Publicado: (2021)

Critical review of cancer risk associated with angiotensin receptor blocker therapy
por: Wuerzner, Grégoire, et al.
Publicado: (2011)

Differential clinical profile of candesartan compared to other angiotensin receptor blockers
por: Cernes, Relu, et al.
Publicado: (2011)

COVID-19, Angiotensin Receptor Blockers, and the Brain
por: Saavedra, Juan M.
Publicado: (2020)

Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation
por: Naccarelli, Gerald V, et al.
Publicado: (2009)

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

Effect of renin angiotensin blockers on angiotensin converting enzyme 2 level in cardiovascular patients
por: Farid fahmy, Sarah, et al.
Publicado: (2023)

Synergistic protective effects of a statin and an angiotensin receptor blocker for initiation and progression of atherosclerosis
por: Lee, Seul-Gee, et al.
Publicado: (2019)

Angiotensin receptor blockers might be protective against hepatic steatosis after liver transplantation
por: Eshraghian, Ahad, et al.
Publicado: (2023)

Angiotensin receptor blockers & endothelial dysfunction: Possible correlation & therapeutic implications
por: Radenković, Miroslav, et al.
Publicado: (2016)

Angiotensin Regulation of Vascular Homeostasis: Exploring the Role of ROS and RAS Blockers
por: Koumallos, Nikolaos, et al.
Publicado: (2023)

Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease
por: Vasavada, Nina, et al.
Publicado: (2009)

Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Prothrombotic Processes and Myocardial Infarction Risk
por: Dézsi, Csaba András, et al.
Publicado: (2016)

From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy
por: Matsoukas, John, et al.
Publicado: (2021)

Angiotensin enzyme inhibitors and angiotensin receptor blockers as protective factors in COVID-19 mortality: a retrospective cohort study
por: Yahyavi, Ashkan, et al.
Publicado: (2020)

Premorbid Use of Beta-Blockers or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with Acute Ischemic Stroke
por: Zeng, Yuanyuan, et al.
Publicado: (2023)

A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors
por: Siragy, Helmy M
Publicado: (2011)

Voltage-gated calcium channel blockers for psychiatric disorders: genomic reappraisal
por: Harrison, Paul J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6m2k8h68q7t62rgn0o2c18nti7